Top Page
EKF Diagnostics Holdings
(LSE:EKF)
EKF Diagnostics Holdings (EKF) vs. S&P 500 (SPY)
EKF Diagnostics Holdings Business Overview & Revenue Model
EKF Diagnostics Holdings Financial Statement Overview
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 52.61M | 66.64M | 81.84M | 65.26M | 44.92M | Gross Profit |
| 23.86M | 24.04M | 39.37M | 37.42M | 23.73M | EBIT |
| 2.08M | 1.91M | 21.75M | 16.89M | 5.78M | EBITDA |
| 7.68M | -2.18M | 27.39M | 20.04M | 10.02M | Net Income Common Stockholders |
| 2.35M | -9.58M | 15.85M | 11.11M | 3.68M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 6.02M | 11.58M | 20.34M | 21.91M | 12.07M | Total Assets |
| 80.85M | 89.29M | 115.12M | 101.27M | 87.13M | Total Debt |
| 4.10M | 1.55M | 2.63M | 1.58M | 1.66M | Net Debt |
| -1.92M | -10.03M | -17.71M | -20.34M | -10.42M | Total Liabilities |
| 12.63M | 14.77M | 20.38M | 23.07M | 15.95M | Stockholders Equity |
| 67.12M | 73.35M | 94.12M | 77.65M | 70.57M |
| Cash Flow | Free Cash Flow | |||
| -664.00K | 3.86M | 4.59M | 11.16M | 2.73M | Operating Cash Flow |
| 6.31M | 9.69M | 10.24M | 13.81M | 5.10M | Investing Cash Flow |
| -5.64M | -8.93M | -5.48M | 1.34M | -2.40M | Financing Cash Flow |
| -3.65M | -11.04M | -6.16M | -5.21M | -634.00K |
EKF Diagnostics Holdings Technical Analysis
EKF Diagnostics Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | £4.42B | 15.80 | 15.79% | 3.08% | 5.83% | 83.35% | |
71 Outperform | £58.60B | 18.76 | 22.52% | 4.21% | 2.57% | -30.13% | |
67 Neutral | £94.78M | 15.22 | 8.95% | 5.71% | -4.59% | 165.38% | |
52 Neutral | $5.35B | 3.96 | -42.60% | 2.86% | 17.58% | 1.27% | |
36 Underperform | £8.09M | ― | ― | -2.80% | -38.55% |
EKF Diagnostics Holdings Corporate Events
EKF Diagnostics Holdings plc has announced the purchase of 200,000 of its ordinary shares at a price of 21 pence per share, which will be held in treasury. This share buyback is part of the company’s strategy to manage its capital structure and maintain the aggregate indirect beneficial interest of Mr. Mills, a non-executive director, at approximately the same level, ensuring it does not exceed 30% of the total voting rights. This move may impact the company’s market positioning by potentially increasing shareholder value and stabilizing its share price.
EKF Diagnostics Holdings plc announced a share buyback, purchasing 200,000 ordinary shares at 21 pence each, which will be held in treasury. This move is part of a strategic effort to manage the company’s capital structure and maintain the aggregate indirect beneficial interest of Mr. Mills, a significant stakeholder, at a stable level. The buyback reflects EKF’s commitment to optimizing shareholder value and may impact the company’s market positioning by potentially increasing share value and demonstrating financial stability.
EKF Diagnostics Holdings plc has published its Annual Report and Accounts for the year ending December 31, 2024, along with the notice for its 2025 Annual General Meeting (AGM). The AGM is scheduled for May 20, 2025, in London, with provisions for shareholders to participate online or via phone. The company encourages shareholders to vote online and submit questions in advance, streamlining the process for engagement and decision-making.
EKF Diagnostics Holdings plc has announced the buyback of 570,915 of its ordinary shares at a weighted average price of 21 pence per share, which will be held in treasury. This move is part of a strategic effort to manage the company’s share capital and maintain the aggregate indirect beneficial interest of key stakeholders, such as Mr. Mills, at a stable level. The buyback is expected to impact the company’s total voting rights, with the new total number of ordinary shares carrying voting rights being 451,539,956. This announcement reflects EKF’s ongoing commitment to optimizing its capital structure and ensuring compliance with regulatory requirements.
EKF Diagnostics Holdings plc has announced the repurchase of 500,000 of its ordinary shares at a price of 21 pence per share, which will be held in treasury. This buyback is part of a strategic move to manage the company’s share capital and maintain shareholder value. The transaction included acquiring shares from Harwood as investment manager to Oryx, ensuring that Mr. Mills’ aggregate indirect beneficial interest remains stable. This action reflects EKF’s ongoing efforts to optimize its capital structure and potentially enhance its market positioning.
EKF Diagnostics Holdings plc announced a share buyback of 278,000 ordinary shares at a weighted average price of 22.5 pence per share, which will be held in treasury. This move is part of a strategic effort to manage the company’s share capital and maintain the aggregate indirect beneficial interest of Mr. Mills, a non-executive director, at approximately the same level, ensuring it does not exceed 30% of the total voting rights. This buyback reflects EKF’s ongoing commitment to optimizing shareholder value and maintaining a balanced capital structure.
EKF Diagnostics Holdings plc has announced the buyback of 278,000 of its ordinary shares at a weighted average price of 22.5 pence per share, which will be held in treasury. This move impacts the company’s total voting rights, now consisting of 452,610,871 shares, and is part of a strategy to maintain shareholder interests, particularly that of Mr. Mills, whose indirect beneficial interest remains stable. The buyback reflects EKF’s ongoing efforts to manage its capital structure and maintain its market position.
EKF Diagnostics Holdings plc has announced a share buyback, acquiring 141,693 ordinary shares at a price of 22.5 pence each, which will be held in treasury. This move is part of a broader strategy to manage the company’s share capital and maintain shareholder value. The transaction included the purchase of shares from Harwood as investment manager to Oryx, ensuring that Mr. Mills’ indirect beneficial interest remains stable. Following this buyback, the total number of shares with voting rights stands at 452,888,871. This strategic financial maneuver is expected to impact the company’s market positioning by potentially enhancing shareholder value and maintaining control over share distribution.
EKF Diagnostics Holdings plc has announced the buyback of 700,000 of its ordinary shares at an average price of 22.0 pence per share, with plans for further purchases up to approximately £1.0 million. This move is part of a strategic effort to manage the company’s capital structure and maintain the indirect beneficial interest of key stakeholders, such as Christopher Mills, at a stable level. The buyback is expected to impact the company’s total voting rights, with the aim of avoiding mandatory takeover obligations under the City Code on Takeovers and Mergers.
EKF Diagnostics Holdings plc announced that several members of its board have purchased a total of 550,000 ordinary shares at 22.0 pence per share. This move by the board members, including the Executive Chair, CEO, and CFO, indicates a strong vote of confidence in the company’s future prospects. The transaction, conducted on the London Stock Exchange’s AIM market, may positively impact the company’s market perception and stakeholder confidence.
EKF Diagnostics Holdings has reported its full-year results for 2024, highlighting a 9.2% growth in adjusted EBITDA and stronger than expected cash generation. The company has focused on higher margin product ranges and core operations, while winding down non-core and low margin product lines. This strategic shift has resulted in improved gross margins and a significant strengthening of its balance sheet. EKF has also announced a five-year strategic development plan aimed at accelerating growth, with a focus on reinvesting in its core business divisions to drive organic growth and margin improvement. The company is considering various options for utilizing its strong cash generation to deliver further value to shareholders.
EKF Diagnostics Holdings plc has appointed Gavin Jones as the new Chief Executive Officer. Gavin, who previously served as Chief Product Officer, brings extensive experience in analytical chemistry and diagnostics, having contributed significantly to product innovation and operational excellence. His appointment is expected to drive sustainable growth and unlock the potential of EKF’s core products and services, with a focus on expanding point-of-care solutions and strengthening market presence in life sciences.
EKF Diagnostics Holdings plc announced it will release its full-year results for 2024 on March 25, 2025. The company will host two investor presentations on the same day, one online and one in-person in London, to discuss the results. These events are open to existing and potential shareholders, providing an opportunity for stakeholders to engage directly with the company’s executive chair and CFO. This approach reflects EKF’s commitment to transparency and stakeholder engagement, potentially enhancing its market position and investor relations.
Schroders PLC has increased its holdings in EKF Diagnostics Holdings PLC by acquiring additional shares, raising its ownership from 4.993768% to 5.008645%. This transaction indicates a significant strategic move by Schroders, potentially impacting EKF’s market dynamics and signaling confidence in the company’s future prospects within the diagnostics industry.